Mirador Therapeutics Announces $400 Million Series A Financing to Advance Precision Therapies for Immune-Mediated Inflammatory and Fibrotic Diseases

Recently, the executive team behind Prometheus Biosciences, an autoimmune disease drug developer, founded a new biotechnology startup named Mirador Therapeutics.

Upon its establishment, the company completed a Series A financing round of over $400 million (RMB 2.888 billion). The round was led by Arch Venture Partners, OrbiMed, and Fairmount, with other investors including Fidelity Management & Research Company, Point72, Farallon Capital Management, Sanofi Ventures, RTW Investments, and Alexandria Venture Investments.

This financing round has secured the largest single funding amount raised by a biotech startup in 2024 to date, and stands as one of the largest Series A financings in the sector in recent years.

Many industry insiders have noted a surge in investment activity, with several biotech startups raising at least $150 million each in March. This investment boom has also attracted more advanced pharmaceutical companies. In a recent report, analysts at the investment bank Jefferies stated that the pace of financing for biotechnology stocks is experiencing its strongest period in three years. Data from BioPharma Dive shows that, in terms of total capital raised, U.S. initial public offerings (IPOs) are also proceeding at their fastest rate since 2021.

After years of downturn in biotechnology investment and financing, the industry is finally showing signs of recovery. The oversubscribed financing round of Mirador Therapeutics has further highlighted the warming trend in the biopharmaceutical sector.

In 2023, Merck & Co. announced the acquisition of biotechnology company Prometheus Biosciences for $10.8 billion, gaining its investigational candidates for ulcerative colitis (UC), Crohn’s disease (CD), and other autoimmune conditions to strengthen the company’s pipeline in immunology.

The helmsman and dealmaker behind it is Mark McKenna, CEO of Mirador and former leader of Prometheus.Just as many believed Mark McKenna could retire with honor after the acquisition of Prometheus, he stated in an interview that his entrepreneurial journey was far from over, as Prometheus had not “fulfilled its original mission.” Consequently, McKenna reunited many members of his former team to establish a company focused on precision treatments for autoimmune diseases. Leveraging their collective experience and extensive data resources, they aimed to develop novel therapeutics for inflammatory diseases of the gut, lungs, and skin. This new venture is Mirador Therapeutics.

“Everything about Prometheus has been far from easy. I believe this journey has been highly meaningful and has built a management team capable of addressing significant challenges,” said McKenna. “There were many tense moments as we repositioned the company, embraced early-stage scientific concepts, and translated them into clinical applications.”

The acquisition of Prometheus not only demonstrated the strength of its pipeline and founding team but also proved that precision medicine can hold a significant place beyond oncology. Therefore, when McKenna considered founding his next company, he had a clear vision for how to assemble the management team. Other founding members of Mirador include Olivier Laurent, former Chief Scientific Officer and Head of R&D at Prometheus, who will serve as Mirador’s CSO, and Allison Luo, former CMO of Prometheus, who will also serve as Mirador’s CMO.

Prometheus’s success has made fundraising significantly easier for Mirador. McKenna stated that the Mirador team completed its financing round in approximately 60 days, rather than taking a full year as Prometheus had done. Many of the investors were previous backers of Prometheus, alongside several new investors.

What is certain is that the $400 million financing round has exceeded expectations; therefore, Mirador will use these funds to advance multiple internal projects into clinical trials, dedicated to developing precision medicines for inflammatory and fibrotic diseases.

Although Mirador has secured over $400 million in financing, its pipeline remains under wraps.What is certain is that,Mirador is building a core technology platform, Mirador360™, this platform provides Mirador with a powerful analytical tool by integrating the latest advances in genetics, data science, and precision medicine, thereby accelerating the company’s new drug development for the treatment of immune-mediated inflammatory and fibrotic diseases.

According to reports, Mirador360™ offers numerous advantages. First, it enables precise scientific data analysis. As one of the most extensive repositories of data on immune-mediated diseases, Mirador360™ is continuously expanding and leverages the latest breakthroughs in human genetics and data science to drive next-generation precision therapies in the field of autoimmunity. Second, current treatments for immune-mediated diseases face a significant challenge: a lack of target differentiation. Mirador360™ is specifically designed to harmonize molecular profiles from millions of patients to discover and validate genetic associations with immune-fibrotic diseases, identify novel therapeutic targets, elucidate interactions between targets, and pinpoint optimal targets for potential combination therapies. Furthermore, Mirador’s emphasis on genetic analysis marks a pivotal shift in drug development for immune-mediated diseases. By focusing on specific patient genetic targets not merely as a strategy but as a core driving force, Mirador360™ also enables Mirador to develop diagnostics and stratify heterogeneous patient populations to facilitate precise clinical development.

It is reported that while operating in stealth mode, Mirador has been actively engaging with potential partners, including extensive discussions at the J.P. Morgan Healthcare Conference in January. McKenna did not disclose specific details, stating that potential partners could range from small biotechnology firms to large pharmaceutical companies. He expects some deals to be finalized in the “coming quarters,” with the aim of accelerating Mirador’s transition into a clinical-stage company.

But this does not mean that Mirador will slow down the progress of its internal pipeline. McKenna expects to submit an Investigational New Drug (IND) application to the FDA next year, and Mirador will draw lessons from its experience in oncology and with Prometheus to establish a series of entirely new treatment methods.